Norditropin Flexpro (Somatropin)

Somatropin mimics the body’s natural growth hormone. After subcutaneous injection it binds to growth‑hormone receptors on target cells, activating the JAK2‑STAT5 signaling cascade, which stimulates hepatic production of insulin‑like growth factor‑1 (IGF‑1). IGF‑1 mediates most of the anabolic and growth‑promoting effects throughout the body.

The dose of Norditropin Flexpro is individualized and determined by the prescribing physician based on the patient’s age, weight, diagnosis, and IGF‑1 response. Dosing regimens may vary from daily low‑dose injections in children to tailored doses for adults, and should always follow the clinician’s instructions.

Safety of somatropin in pregnancy and lactation has not been established. It is generally contraindicated unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Norditropin Flexpro is a recombinant somatropin delivered via a pre‑filled pen, offering convenient dosing and precise dose adjustments. Compared with vial‑based formulations, the pen reduces preparation time and dosing errors. Efficacy and safety are comparable to other approved human growth hormone brands when used according to prescribing information.

The product must be stored refrigerated between 2 °C and 8 °C (36 °F–46 °F). Keep it in the original carton to protect from light, do not freeze or shake the pen. Once in use, the pen can be kept at room temperature for a limited period as indicated in the package insert, but should be discarded after the recommended usage time.

Norditropin Flexpro is supplied as a solution for subcutaneous injection in a pre‑filled pen. The pen is primed according to the manufacturer’s instructions, and the prescribed dose is delivered by pressing the dose button and injecting into the subcutaneous tissue of the abdomen, thigh or upper arm. Injections are typically given once daily, preferably at the same time each day.

Serious adverse events include intracranial hypertension, which may present with severe headache and visual disturbances, slipped capital femoral epiphysis, severe allergic reactions such as anaphylaxis, and possible acceleration of tumor growth in patients with active malignancy. Patients should be monitored regularly for these conditions, and any concerning symptoms should prompt immediate medical evaluation.

Norditropin Flexpro is contraindicated in individuals with known hypersensitivity to somatropin or any excipients, active malignancy, or uncontrolled diabetes. It should also be avoided in patients with acute critical illness following trauma or major surgery. Physicians should assess each patient’s medical history before initiating therapy to ensure suitability.